CD8A and colorectal cancer: Galactose-based miR-122 targeting lipid calcium phosphate (Gal-LCP) nanoparticles were linked to elevated CD8+/CD4+ T cell ratios and decreased immunosuppressive cell infiltration, making the liver more receptive to antitumor immune responses, which may have successfully stopped colorectal cancer liver metastases and extended survival (50, 51).